PodcastThe Directors The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient livesIn a time of uncertainty, “react to the knowns, not the fear” May 16, 2025Vol.51 No.19By Katie Goldberg
Capitol Hill Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFsTo avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges May 16, 2025Vol.51 No.19By Jacquelyn Cobb and Claire Marie Porter
Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reducedNCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.” May 16, 2025Vol.51 No.19By Jacquelyn Cobb
Guest Editorial An opportunity for Trump: Position U.S. cancer science to lead the world May 16, 2025Vol.51 No.19By Wafik S. El-Deiry
FreeGuest Editorial First exhibit at Museum of Medicine and Biomedical Discovery to focus on the history of cancer researchFrom despair to discovery to triumph May 16, 2025Vol.51 No.19By Mace L. Rothenberg
Sponsored City of Hope research showcases innovation at 2025 AACR annual meeting May 16, 2025Vol.51 No.19By City of Hope
FreeIn the Archives Ashtrays in ivory towers: Two centuries of tobacco’s ties to academia May 16, 2025Vol.51 No.19
Trump administration is removing the mainstays of NCI and the federal government’s cancer programPeer review, registries, and evidence-based patient information take a big hit May 09, 2025Vol.51 No.18By Paul Goldberg and Jacquelyn Cobb
Guest Editorial George Weiner: Cancer centers are special, as are site visits in CCSG review May 09, 2025Vol.51 No.18By George J. Weiner
Regulatory News Cyber-iconoclast Vinay Prasad named head of FDA’s CBERAn oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies May 09, 2025Vol.51 No.18By Claire Marie Porter
